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Subpopulations of Normal Peripheral Blood and Bone Marrow Cells Express a Functional Multidrug Resistant Phenotype
By Doris Drach, Shourong Zhao, Johannes Drach, Radha Mahadevia, Claus Gattringer, Heinz Huber, and Michael Andreeff
The multidrug-resistance gene, MDRl is expressed in many normal tissues, but little is known about its expression in normal hematopoietic cells. Using the monoclonal antibody C219 and flow cytometric analysis, P-glycoprotein (P-gp) was found t o be expressed in all peripheral blood (PB) subpopulations (CD4, CD8, CD14, CD19, CD56) except granulocytes. To specifically determine MDRl gene expression, these PB subpopulations were isolated by fluorescence-activated cell sorting (FACS) and analyzed for MDRl mRNA by polymerase chain reaction (PCR). All subsets were positive by PCR, but only minimal MDRl mRNA was detected in monocytes and granulocytes. Significant efflux of Rhodamine-123 (Rh-123). a measure of P-gp function, was detected in CD4+, CD8+, CD14+, CD19+, and CD56+ cells but not in granulocytes.
Next, PCR-analysis was performed on FACS-sorted bone marrow (BM) cells t o assess MDRl expression in different
ELLULAR RESISTANCE to antineoplastic drugs C represents a major problem in clinical oncology. One type of resistance, induced by structurally unrelated drugs, such as vinca alkaloids, anthracyclins, and epipodophyllotoxins, is termed multidrug resistance (MDR). MDR has been related to overexpression of the MDRl gene and production of a 170 to 180 Kd membrane-associated P-glycoprotein (P-gp). P-gp is believed to function as an energy-dependent drug efflux pump for various lipophilic xenobiotics, resulting in reduced intracellular accumulation. P-gp is not only expressed by malignant cells but has been also identified in normal tissues with excretory function, such as the proximal tubules of the kidney, and in liver biliary ducts.' P-gp was also detected in endothelial cells of the blood-brain barrier.* With regard to hematopoiesis, little is known about MDRl gene expression in normal bone marrow (BM) and peripheral blood (PB) cells. Although low expression of MDRl mRNA has been described in blood and BM sample^,^ P-gp expression could not be detected in these cells by immunohistochemical assays.l14 Expression and activity of P-gp has been shown in BM progenitor cells5 and recently, MDRl mRNA could be detected by in situ mRNA hybridization in a subset of cells with myeloid and lymphoid morphology, respectively.6 Andreeff and Hegewisch detected expression of P-gp in peripheral blood cells with the monoclonal antibody (MoAb) HYB241 and a sensitive statistical technique (the Kolmogorov-Smirnov test) to analyze flow cytometric data (unpublished observation, March 1988). Therefore, we investigated the expression of MDRl mRNA and of P-gp in normal blood and BM cells to define its distribution in different hematopoietic lineages and maturational stages and investigated the functional activity of P-gp by means of rhodamine-123 (Rh-123) efflux in these PB and BM subpopulations. The multiple myeloma parent cell line 8226/S and its doxorubicinresistant mutants 8226/DOX6 and 8226/DOX40 were kindly provided by Dr W. S. Dalton (University of Arizona, T~c s o n ) .~ All cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 1% penicillin, 1% streptomycin, and 1% L-glutamine (all from GIBCO-BRL, Gaithersburg, MD). Cell cultures were maintained at 37°C in a humidified 5% C02/95% air atmosphere. Using the MoAb HYB-241 it was recently shown that different amounts of P-gp were expressed in DOX-6 and DOX-40 cells, which were inversely related to the uptake of daunorubicin. 8 The following MoAbs were used: Leu-4/CD3, Leu-3/CD4, Leu-M3/CD14, Leu-MUCD15, Leu-12KD19, Leu-M9/CD33, Leu-l9/CD56, goat-anti mouse Ig (AMAC, Westbrook, ME), and OKT-8/CD8 (Ortho Diagnostic System, Raritan, NJ). All MoAbs were used at saturation concentrations following the manufacturers' recommendations. Incubation was performed for 30 minutes on ice, followed by two washes with PBS. Isotypic control antibodies (Becton Dickinson) were used in all experiments.
MATERIALS AND METHODS

Cells
C-219 MoAb against P-gp was obtained from Centocor Diagnostics (Malvern, PA). A previously published staining protocol was used9 and slightly modified for double-staining of surface markers and P-gp. Briefly, after staining of the surface antigen, cells were fixed in paraformaldehyde (0.8% in PBS) at 4°C for 2 minutes, permeabilized with methanol 70% at -20°C for 2 minutes, and incubated with C-219 (2.5 &mL) for 60 minutes.
Efflux of Rh-123 (Sigma) was studied as previously describeds with minor modifications. Briefly, for double labeling with surface markers and Rh-123, cells were stained with MoAb against the surface antigen as described above and incubated with 200 nglmL Rh-123 in 1 mL of media for 15 Rhodamine efflux studies. (8226/DOX-6, 8226/DOX-40) minutes at 3PC, washed twice in ice cold RPMI-1640 medium, and then transfered into dye-free medium with or without 10 bg/mL verapamil and incubated at 37°C for 90 minutes.
Rh-123 efflux data were statistically analyzed using Student's f-test for independent samples. Within each subpopulation, the percent decrease of mean fluorescence with and without verapamil was compared. Flow cytometric measurements were quantitated using the Kolmogorov-Smirnov analysis.I0
Flow cytometric analysis and cell sorting was conducted with a FACStar PLUS flow cytometer (Becton Dickinson), equipped with an argon ion laser (Spectra Physics, Mountain View, CA) operated at 488 nm and 300 mW. Green (FITC, Rh-123) and red (phycoerythrin) fluorescence was detected using 530/30 nm and 585/40 nm bandpass filters, respectively. Spectral overlap between green (FITC, Rh-123) and red (PE) signals was electronically compensated. Data acquisition and analysis was performed with the FACStar PLUS Research software (Becton Dickinson). Forward and side scatter signals were collected using linear scales, and fluorescence signals were collected on logarithmic scales. Cells displaying more fluorescence than their controls were considered positive. Cell sorting was performed using the Normal R sorting mode. All cells were kept on ice during the sorting procedure. An aliquot of sorted cells was reanalyzed for purity.
IWA preporation and polymerase chain reaction (PCR). Total cellular RNA was isolated according to the acid-guanidiniumphenol-chloroform technique." cDNA was synthesized with a cDNA synthesis kit obtained from Boehringer Mannheim Corp (Indianapolis, IN) following the manufacturer's instructions. PCR was performed using cDNA synthesized aliquots from 50 ng of RNA, 150 ng of each MDR1-specific primer, 1.5 U of TaqSfafisrical analysis. Roninson and used as previously described.' p2-Microglobulin was used as control as previously de~cribed.~ Each cycle contained a denaturation step at 94°C for 1 minute, an annealing step at 63°C for 1 minute, and an elongation step at 72°C for 2 minutes. A total of 32 cycles was performed followed by a final elongation step at 72°C for 10 minutes, using an automatic PCR processor (Perkin Elmer Cetus, Norwalk, CT).
Ten-microliter aliquots of the PCR products were separated electrophoretically through a 6% acrylamide gel (BIO-RAD, Richmond, CA) for 2 hours and subsequently exposed overnight to a Kodak X-Omat film (Eastman Kodak, Rochester, NY) at -70°C without intensified screen. 32P incorporation was quantitated by radioactivity measurements using Betascope 603 (Betagen, Waltham, MA).
All experiments were performed in duplicate from 3 to 7 PB and BM samples.
RESULTS
Expression of P-gp is detectable by MoAbs when mononuclear PB cells are analyzed. To determine which normal cells express the protein, double staining with lineagespecific surface antibodies and C-219 (an MoAb that recognizes a cytoplasmic epitope of P-gpI2) was performed (Fig 1) Analysis of normal unseparated PB and BM cells for MDRl mRNA was positive (data not shown). PB cells from three healthy volunteers were stained with lineage-specific MoAbs and subsequently sorted by FACS. Staining was performed with antibodies for pan-T-cells (CD3), major T-cell subsets (CD4, CD8), NK cells (CDS6), B cells (CD19), monocytes (CD14) and granulocytes (CD15). Subpopulations ranged from 3.8% to SS%, and the purity after sorting was 98.3% rt 0.98% (median ? SD). Immediately after sorting, RNA was extracted and analyzed for MDRl mRNA by PCR amplification using MDR1-specific prime r~.~ A sensitive (8226/S) and two multidrug-resistant T-cell subsets were studied in seven normal individua1s;in all cases, CD8+ cells appeared to have higher levels of MDRl expression than CD4+ cells. This was confirmed by quantitative 32P measurements of MDRl and p2-microglobulin using the Betascope: For CD8+ cells, the ratio was significantly higher than for CD4+ cells (Fig 4) . Monocytes and granulocytes expressed MDRl mRNA at very low levels.
To investigate MDRl expression during hematopoietic differentiation, the following BM subsets were studied in three normal individuals: CD34+ (progenitor cells), CD33+/ CD34+ (myeloid progenitors), CD33+/CD34-(myeloid cells), CD33++/CD34-(monocytic cells), CDlO+/CD19+ (early B cells), CDlO-/CD19+ (mature B cells) and glycophorin A+ cells (erythroid precursors). BM subpopulations comprising 2.8% to 39.2% of unsorted BM were enriched to 96.1% 2 3.1% (median 2 SD) by the sorting procedure. As shown in Figs 3 and 4 , CD34+ cells were positive forMDR1; within this population, myeloid-committed progenitors (CD33+/CD34+) expressed MDR1, whereas only a faint band was detected in CD34-negative myeloid cells. Monocytic cells at a more differentiated stage did not show any MDRl expression. In B cells, MDRl was detectable in both early and late maturational stages. Erythroid cells expressed MDRl only at extremely low levels. This could be attributable to the 4.4% contamination with remaining glycophorin A negative cells after the sorting procedure. A dilution experiment with 8226/S and 8226/DOX-40 cells, which have an MDRl /P2-microglobulin ratio comparable to T cells (Fig 4) , was performed to test whether a low percentage of MDR1-expressing cells could cause positivity in this PCR-assay. Even 1% 8226/DOX-40 cells admixed to 8226/S cells resulted in detectable MDRl expression using the same conditions as in the analysis of the PB and BM cells (data not shown).
Finally it is of importance to show that P-gp is not only present but also functionally active in normal cells. Efflux of Rh-123 was applied as a functional test using 8226/S and 8226/DOX-6 cell lines as negative and positive controls (Fig SA) . PB and BM cells were double stained with surface MoAb and Rh-123 and efflux was measured in the presence and absence of verapamil. In PB, significant efflux was seen in all lymphocyte subpopulations, which was most prominent in NK cells. In monocytes and granulocytes, a slight decrease of Rh-123 mean fluorescence was found after 90 minutes, but compared with the controls without verapamil, this decrease was significant only in CD14+ cells at a level of P < .05. In BM, CD34+ cells effluxed the dye as did CD10+, CD33+, and CD33++, but to a lesser extent. In glycophorin A+ cells, the efflux was not significantly different from its control (P > .OS). 
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To test whether residual normal cells could influence the assessment of MDRl expression in patient samples, we analyzed sorted blast cells and normal T cells from two leukemic patients for MDRl expression (newly diagnosed AML, relapsed CALL). In both samples, not only blast cells but also T cells were shown to be positive (Fig 6) .
DISCUSSION
This study investigates the expression of P-gp and MDRl mRNA in blood and marrow cells from normal individuals. P-gp was found to be expressed and functionally active in all PB subpopulations except in granulocytes. Following reverse transcription PCR, a band for MDRl mRNA was detected in all PB-subpopulations. Both expression and function appeared to be highest in NK cells and CD8+ T cells, as determined by 32P-incorporation during PCR and by Rh-123 efflux measurements.
Previous studies showed that normal lymphocytes have the ability to eliminate Rh-123I4J5 and to bind the antibody HYB241 (unpublished observation, March 1988), suggesting an MDRl-like activity in these cells. However, these studies did not investigate the expression of P-gp or MDRl mRNA in specific cell types. The data reported here provide evidence that subpopulations of normal PB cells express MDRl mRNA at different levels. This pattern is consistent with the results of rhodamine-efflux studies,I4J5 and we can now attribute those findings specifically to MDRl expression.
Antibody studies have shown that P-gp is expressed in CD34+ progenitor c e k 5 In a recent publication, in situ mRNA hybridization showed positivity for MDRl in a subset of BM cells that could be assigned to the myeloid and lymphoid lineage.h Therefore, it was of interest to analyze MDRl expression in marrow cells of different hematopoietic lineages and maturational stages. In a purified (97.7%) population of normal CD34+ progenitor cells, MDRl mRNA was found at high levels. MDRl was also detected in myeloid-committed progenitors (CD33+/ CD34+), CD34-negative myeloid cells, and in different subsets of B-cell maturation, but not in CD34-negative monocytic cells. In contrast, the Rh-123 efflux study showed pumping activity in a CD33++ monocytic BM population, which suggests P-gp expression at least at an early stage of monocytic differentiation. The Rh-123 study showed a decrease in the mean fluorescence for Rh-123 in all BM subpopulations. This efflux could be blocked by verapamil, which implies that the efflux is caused by P-gp. Glycophorin A+ BM cells showed no significant efflux of Rh-123 and 32P-incorporation during PCR was very low. Because the glycophorin-A-positive population was only 95.6% pure, we cannot definitely conclude that erythroid cells express MDR1. We have found that contamination of MDRlnegative cells with as few as 1% MDR1-positive cells results in MDRl positivity using the PCR technique.
The finding that MDRl is expressed in normal blood cells has important implications for MDR studies of patient samples. In a leukemia sample with a mixture of normal and leukemic cells, positive results may be attributable to residual normal cells. Likewise, MDRl expression in normal cells has implications for the interpretation of results obtained from lymph nodes and other tissues with high numbers of reactive lymphocytes. Because none of the published studies16-22 were performed on "pure" leukemic cells, the results have to be interpreted with caution. Depending on the sensitivity of the assay used, it is possible that low levels of residual normal cells do not influence the results of MDR studies. However, if a sensitive technique like PCR is applied, it is necessary to study the MDR phenotype exclusively within the malignant cell population. Also, determination of the level of gene expression may be influenced by the presence of normal cells, which could lead to overestimates or underestimates of the actual MDRl level in malignant cells.
Our study also raises the question of the physiologic role of MDRl in normal leukocytes. As P-gp is known to function as an efflux pump, it may facilitate the extrusion of use only.
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For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From toxic or perhaps even regulatory substances in these cells. Do lymphocytes use P-gp as a pump for enzymes and other factors exerting immunologic effects? What level of MDRl expression is of clinical significance in malignant cells? Furthermore, expression of MDRl in hematopoietic progenitor and functional, differentiated cells may render them more vulnerable to chemotherapy if a P-gp inhibitor is administered at the same time. Increased myelosuppression was observed in one clinical trial using cyclosporine A and etoposide in c o m b i n a t i~n ,~~ but the physiologic and pathophysiologic roles of P-gp have to be better defined to fully understand the implications for chemotherapy/P-gp antagonist combination therapies.
Our data provide evidence that normal PB and BM cells express MDRl and that its gene product P-gp is functionally active in these cells. These results have to be considered in the analysis of MDRl expression in any tumor sample that may contain normal blood cells.
